PTD-DBM's commercial supply is thinner than any of the copper peptides covered elsewhere on this site. The foundational research programme, tracing from an osteoporosis discovery through wound healing to the hair-specific application, was published across 2015 to 2017, and most of the cosmetic industry hasn't caught up with it. At the time of writing, we're aware of at least one other brand, US-based, producing a PTD-DBM serum at 0.001%, a tenth of AmpleLab's concentration. Whether a higher concentration produces better real-world outcomes hasn't been established in human trials. The comparison here is purely one of disclosed formulation.

AmpleLab's 0.01% PTD-DBM Hair and Scalp Serum is formulated in the UK as a single-active serum, with concentration, INCI, and mechanism documented publicly, rather than left for the buyer to guess at.

PTD-DBM is a synthetic peptide developed at Yonsei University, designed to competitively block CXXC5, a protein that suppresses Wnt/beta-catenin signalling in hair follicles. It's a mechanistically distinct approach from the androgen-pathway and vascular mechanisms addressed by finasteride, dutasteride, and minoxidil, targeting a molecular checkpoint inside the follicle cell itself.

It's worth being direct about the evidence stage: the research is pre-clinical, mouse models and in vitro human cell studies. No completed human clinical trials exist yet. Full mechanism and evidence detail is covered in our main PTD-DBM article.

PTD-DBM is formulated at 0.01% (100mcg/mL), stated explicitly on the product page. As a large fusion peptide, it doesn't cross the skin barrier unassisted; the formula uses Methyl Vanillate, a small molecule with its own independent Wnt/beta-catenin research history, as a penetration enhancer rather than DMSO, which is the more common approach elsewhere in this compound class. We cover why that distinction matters in our article on Methyl Vanillate.

The carrier is a glycol-free aqueous solution, the same carrier architecture used across the AmpleLab range. No propylene glycol or butylene glycol, and no DMSO, a solvent commonly used elsewhere to help large peptides penetrate skin but one that carries its own non-selective penetration-enhancing properties that complicate use alongside other topicals or microneedling.

AmpleLab products are cosmetic formulations and are not intended to diagnose, treat, cure, or prevent any condition. The research referenced for PTD-DBM is pre-clinical; no clinical hair regrowth claims are made.

AmpleLab.